RAMOSE Phase II trial finds promising results for osimertinib and ...
Dec 10, 2024 · 1. Treatment of patients with tyrosine kinase inhibitor (TKI)-naïve epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with osimertinib and ramucirumab resulted in a significantly longer progression-free survival (PFS) compared with osimertinib alone. Evidence Rating Level: 1 (Excellent) Study Rundown: The current standard of care for patients with advanced EGFR ...
Adjuvant durvalumab therapy improves survival in limited-stage …
Nov 21, 2024 · 1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer (SCLC). 2. Durvalumab had a tolerable safety profile, with a comparable incidence of adverse effects to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Small
Adjunctive middle meningeal artery embolization may reduce the ...
Dec 12, 2024 · 1. In this randomized controlled trial, middle meningeal artery embolization plus surgical evacuation was associated with a lower risk of hematoma recurrence or progression in patients with a symptomatic subacute or chronic subdural hematoma. 2. The 90-day mortality appeared to be higher in the treatment group than the …
Influenza vaccination may reduce secondary infection spread …
Dec 1, 2024 · 1. Influenza vaccination was associated with a reduced risk of secondary influenza infections among household contacts, with an estimated effectiveness of 21%. Evidence Rating Level: 2 (Good) Influenza vaccinations are recommended for all individuals aged 6 months and older in the United States for the prevention of influenza infection. However, while the effectiveness of influenza
Radiotherapy with cetuximab or durvalumab for advanced HNSCC
Nov 18, 2024 · 1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the cetuximab group with HR 1.33 (non-significant). 2. Regarding safety, grade 3-4 adverse events occurred in 61% for durvalumab and 79% for cetuximab. Evidence Rating Level: 1 (Excellent) Study Rundown: Concurrent radiotherapy with cisplatin is the standard treatment for locoregionally advanced
Landmark Trials & Summaries: The Classics in Medicine - 2 Minute …
Title Year Journal Citations Key findings; The UKPDS: Reducing the risk of diabetes-related morbidity and mortality: 1998: Lancet: 20,000: 1. For patients with type 2 diabetes mellitus, pharmacologic blood glucose control with sulfonylureas or insulin significantly reduces the risk of microvascular complications, but not macrovascular complications
MRI-informed biopsy recommendation reduces overdiagnosis in …
Oct 9, 2024 · 1. In this randomized controlled trial of men aged 50 to 60, forgoing prostate biopsies in those with elevated PSA but negative MRI reduced the diagnosis of clinically insignificant cancer. 2. MRI-negative men who did not undergo prostate biopsy did not have higher rates of incurable cancer diagnoses in follow-up screenings. Evidence Rating Level: 1
Finerenone reduces heart failure events in patients with HFpEF
Nov 26, 2024 · 1. In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, finerenone treatment was associated with lower rates of worsening heart failure events. 2. Finerenone treatment was not associated with an increase in serious adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Finerenone, a nonsteroidal mineralocorticoid ...
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
Sep 9, 2024 · In-Depth [randomized controlled trial]: This phase 3, multicenter, open-label trial enrolled adults with stage IV clear-cell renal-cell carcinoma who had disease progression after treatment with immunotherapy and a VEGFR-TKI and randomized them (1:1) to belzutifan (n=374) or everolimus (n=372). Median follow-up time was 18.4 months for the first interim analysis and 25.7 months for the second ...
Invasive treatment not superior to medical therapy in older adults …
Dec 10, 2024 · 1. In this randomized controlled trial, in older adults with non-ST-segment elevation myocardial infarction (NSTEMI), invasive treatment did not significantly reduce the composite risk of cardiovascular death or nonfatal MI compared to conservative treatment. 2. There were fewer occurrences of fatal or nonfatal MI in patients in the invasive-strategy group than in the conservative-strategy group.